Guidance Watch: 2 Companies Bullishly Raising Forecasts

The 2025 Q2 earnings season proved resilient, with S&P 500 companies reporting an 11.6% earnings and 5.8% revenue growth year-over-year, alongside high beat rates, leading to positive Q3 expectations. Palantir (PLTR) and Eli Lilly (LLY) were notable outperformers, both delivering strong Q2 results and raising FY25 guidance. PLTR's total sales surged 48% driven by AI demand and robust commercial/government revenue, leading to analyst upgrades. LLY posted $15.5 billion in sales, up 38% YoY, primarily from key drug volume growth, prompting increased FY25 forecasts and insider share purchases.

Analysis

The Q2 2025 earnings season has demonstrated significant resilience, with reported S&P 500 companies delivering an 11.6% year-over-year earnings increase on 5.8% revenue growth, alongside strong beat rates exceeding 78% for both metrics. Against this positive backdrop, Palantir (PLTR) and Eli Lilly (LLY) stand out for their exceptional performance and subsequent guidance upgrades. Palantir capitalized on intense AI demand, reporting a 48% YoY surge in total sales, driven by explosive growth in its US commercial (+93%) and government (+53%) revenues, leading to a 15% EPS beat and upward revisions to its FY25 outlook for revenue and profitability. Eli Lilly demonstrated significant commercial momentum, with revenue climbing 38% YoY to $15.5 billion, propelled by massive volume growth in key drugs Zepbound (+172%) and Mounjaro (+68%). This performance, which included gross margin expansion to 84.3%, prompted an increase in LLY's FY25 revenue and EPS guidance, a move reinforced by notable insider share purchases from the CEO and several directors.

Key Decisions for Investors

• For Palantir, the combination of a significant earnings beat, robust 48% revenue growth, and upwardly revised FY25 guidance solidifies its position as a key AI holding, and investors should monitor execution on its raised commercial and government revenue targets.
• Eli Lilly's strong results, driven by exceptional sales growth in its key drugs and combined with positive guidance revisions and significant insider buying, may present a compelling entry point for investors, especially given the stock's recent 11% year-to-date underperformance.
• Investors should weigh the distinct opportunities presented: Palantir as a high-conviction growth investment driven by accelerating AI adoption, and Eli Lilly as a large-cap biopharma play with clear product catalysts and signs of a valuation turnaround supported by insider confidence.